Im­muno­Gen prices $325M pub­lic of­fer­ing af­ter con­fir­ma­to­ry tri­al in ovar­i­an can­cer

Im­muno­Gen tout­ed pos­i­tive da­ta from a con­fir­ma­to­ry tri­al test­ing out its drug Ela­here for ad­vanced ovar­i­an can­cer on Wednes­day, and to close out the week …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER